ADRB1 and Skeletal myopathy: Even though the use of non-selective β-blockers with antioxidant and vasodilatory effects have impact on counteracting some features of HF-induced skeletal myopathy [42], the use of β1-AR selective β-blockers (cardiac action with minimal effect on skeletal muscle) with vasodilatory and antioxidant properties could have even higher effect counteracting skeletal myopathy considering that preserved β2-AR signalling could potentiate these peripheral effects.